Bard1 Life Sciences Limited

BARD1 is developing a pipeline of blood-based liquid biopsy cancer tests utilising the novel cancer sugar-binding protein, SubB2M, developed by researchers at the University of Adelaide and Griffith University.

In pilot clinical studies using surface plasmon resonance, SubB2M has demonstrated excellent sensitivity and specificity (both >95%) for cancer detection in serum from all stages of breast cancer. This project aims to develop and commercialise two new high-throughput serum-based ELISA-format assays suitable for clinical pathology laboratories for detection of breast cancer recurrence in treatment monitoring, and as an adjunct to screening mammography.


BTB Round: Two

State: Victoria

Project partners: Institute of Glycomics, Griffith University & University of Adelaide

Funding:

  • MTPConnect Grant: $372,654
  • Industry Contribution: $863,654

Duration: September 2020 – June 2022


Visit BARD1 to learn more  |  Twitter: @BD1LSL  |  LinkedIn: Bard1 Life Sciences Ltd

Contact: Dr Peter French